Sipuleucel-T Based Autologous Cellular Immunotherapy for Advanced Prostate Cancer — Stella

Clinical trial discovery in plain English. Data sourced from ClinicalTrials.gov.

ClinicalTrials.gov ↗

Stella is not a medical provider and does not give medical advice. AI-generated summaries are for informational purposes only. Always consult your doctor before making any healthcare decisions.

Sipuleucel-T Based Autologous Cellular Immunotherapy for Advanced Prostate Cancer — Stella

Recruiting

Back to Metastatic Castration-Resistant Prostate Cancer (mCRPC) trials

Phase 1 — Early testing in a small group of people (usually 20–80) to evaluate safety, determine safe dosage, and identify side effects.

Trial locations(1 site)

United States

University of Oklahoma Health Sciences Center, Stephenson Cancer Center, Oklahoma City, Oklahoma

Key details

Phase

Early testing

Sponsor

University of Oklahoma

Collaborators

Dendreon

Enrollment target

~13 participants

Started

November 2023

Primary completion

June 2026

Age range

18 Years and older

Sex

Male only

Last updated March 2026

Interested in joining?

Tell us you're interested and we'll help connect you with the research team. We'll never share your email without your permission.

Your name

Email address

Follow this trial

Get notified in plain English when this trial's status changes. No account required.

View full record on ClinicalTrials.gov